Interní Med. 2004; 6(4): 200-204

Antidepresiva SSRI v léčbě deprese a úzkostných poruch

doc. MUDr. Vladimír Pidrman, Ph.D

Keywords: depression, anxious disorders, SSRI, panic disorder, generalised anxious disorder, posttraumatic stress disorder, obsessively compulsive disorder, social phobia.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pidrman V, D P. Antidepresiva SSRI v léčbě deprese a úzkostných poruch. Interní Med. 2004;6(4):200-204.

doc. MUDr. Vladimír Pidrman, Ph.D.

Psychiatrická klinika FN a LF UP v Olomouci

Autor uvádí přehled výskytu úzkostných poruch a deprese v naší populaci, popisuje jejich hojnou vzájemnou komorbiditu, která je zvláště pro nepsychiatry velmi důležitá. Ukazuje, že nejen samostatná prevalence, ale vzájemná komorbidita deprese a řady úzkostných poruch je vysoká a představuje tak závažnou terapeutickou výzvu. Následně podává přehled indikací a dávkování jednotlivých antidepresiv skupiny SSRI v léčbě úzkostných poruch.

SSRI antidepressants in the treatment of depression and anxious disorders

Author presents an overview of incidence of anxious disorders and depression in our population, describes their frequent co-morbidity, which is especially important for non-psychiatrists. He presents, that not only prevalence alone, but mutual co-morbidity of depression and many anxious disorders is high thus presenting serious therapeutic challenge. Further on, he gives an overview of indications and dosages of single antidepressants of SSRI group in the treatment of anxious disorders.

Download citation

References

  1. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depresion and Anxiety. J Clin Psychiatry 1998; 59 (Suppl 8): 47-54.
  2. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001; 62 (Suppl 11): 53-58.
  3. Basire S. Psychotropic drug directory 2002. Mark Alen Publishing, Ltd., Jesses Farm, 2001; 340 s.
  4. Gould RA, Otto MV, Pollack MH. A meta analysis of treatment outcome for panic disorder. Clin Psychology Rev 1995, 15: 819-844. Go to original source...
  5. Goldberg D. The management of anxious depression in primary care. Journal of Clinical Psychiatry 1999; 60 (Suppl 7): 39-42.
  6. Gorman JM. Kent JM. Sullivan GM. Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. American Journal of Psychiatry 2000; 157 (4): 493-505. Go to original source... Go to PubMed...
  7. Henn F, Sartorius N, Helmchen H, Lauter H. Contemporary psychiatry. Springer, Berlin, 2001; 2258 s. Go to original source...
  8. Kessler RC. The prevalence of psychiatric comorbidity. In: Wetzler S, Sanderson WC, eds, Treatment Strategies for Patients with Psychiatric Comorbidity. New York: Wiley, 1997; 23-48.
  9. Kessler R. Posttraumatic stress disorder: the burden to the individual and to society. J Clin Psychiatry 2000; 61 (Suppl 5): 4-12.
  10. Lader M. The clinical relevance of treating social phobia. J Affect Disord 1998; 50 (Suppl1), S29-34. Go to original source... Go to PubMed...
  11. Látalová K, Pidrman V. Farmakologický přehled: Anxiolytická léčba. Lege artis 1, 2001; 9: 23-26.
  12. Lecrubier Y. Ustun TB. Panic and depression: a worldwide primary care perspective. International Clinical Psychopharmacology, 1998; 13 (Suppl 4): S7-11. Go to original source...
  13. Lydiard RB. The role of drug therapy in social phobia. J Affect Disord 1998; 50 (Suppl 1): S 35-39. Go to original source... Go to PubMed...
  14. Malhi GS, Bridges PK. Management of depression. Marin Dunitz, London, 1998; 130 s.
  15. Montgomery SA, den Boer JA. SSRIs depression and anxiety. John Wiley abd Sons, Chichester, 1998; 194 s.
  16. Pidrman V. Deprese a kardiovaskulární onemocnění. Maxdorf, Praha, 2. doplněné vydání, 2002; 48 s.
  17. Pidrman V. Obsedantně kompulzivní porucha. Galén, Praha, 1999; 32 p.
  18. Preskorn SH. Clinical pharmacology of SSRI. Professional Communication, Inc. 1996, Caddo, 226 s.
  19. Preskorn SH. Outpatient management of depression. Professional Communication, Inc., Caddo, 1999; 256 s.
  20. Sartorius N, Ustun TB, Lecrubier Y, Wittchen HU. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. British Journal of Psychiatry - Supplementum 1996; (30): 38-43. Go to original source...
  21. Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drug Aging, 2001; 18 (5): 355-368. Go to original source... Go to PubMed...
  22. Stahl MS. Don´t ask, don´t tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry, 63, 2002; 9: 756-757. Go to original source... Go to PubMed...
  23. Stahl MS. Psychopharmacology of antidepressants. Martin Dunitz, London, 1997; 114 s.
  24. Stein DJ, Hollander E. Anxiety disorders comorbid with depression. Martin Dunitz, London, 2002; 72 p. Go to original source...
  25. Stein DJ, Stahl S. Serotonin and anxiety: current models. International Clinical Psychopharmacology 2000; 15 (Suppl 2): S1-6. Go to original source... Go to PubMed...
  26. Thomsen PH. Obsessive-compulsive disorder:pharmacological treatment. Eur Child Adolesc Psychiatry. 2000; 9 (Suppl 1): 76-84. Go to original source... Go to PubMed...
  27. Thorpe L, Whitney DK, Kutcher SP, Kennedy SH, et al. Clinical Guidelines for the treatment of depressive disorders. VI. Special populations. Canadian Journal of Psychiatry, June, 2001; 46 (suppl. 1): 63S-76S. Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.